Rezolute (RZLT) Projected to Announce Earnings on Wednesday

Key Points

• Rezolute is expected to report Q4 2026 earnings after the market closes on September 16, with analysts forecasting a loss of $0.1479 per share. The earnings call is scheduled for September 18 at 4:00 p.m. ET.
• Shares fell 3.9% to open at $4.40, while the company has a market capitalization of approximately $423.7 million. Institutional investors own about 83% of the stock.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $9.38, substantially above the current share price. Rezolute is developing treatments for metabolic diseases, including lead candidate RZ358 for congenital hyperinsulinism.

Rezolute (NASDAQ:RZLT - Get Free Report) is expected to be announcing its Q4 2026 results after the market closes on Wednesday, September 16th. Analysts expect Rezolute to post earnings of ($0.1479) per share for the quarter. Parties are encouraged to explore the company's upcoming Q4 2026 earning results page for the latest details on the call scheduled for Friday, September 18, 2026 at 4:00 PM ET.

Rezolute Trading Down 3.9%

Shares of NASDAQ RZLT opened at $4.40 on Wednesday. The stock has a fifty day simple moving average of $4.79 and a two-hundred day simple moving average of $3.95. Rezolute has a 1-year low of $1.07 and a 1-year high of $11.46. The firm has a market cap of $423.68 million, a price-to-earnings ratio of -5.37 and a beta of 0.60.

Institutional Investors Weigh In On Rezolute

Hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its holdings in shares of Rezolute by 5.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,201 shares of the company's stock worth $312,000 after buying an additional 1,567 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Rezolute by 5.5% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,659 shares of the company's stock worth $363,000 after acquiring an additional 2,014 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Rezolute by 8.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 45,088 shares of the company's stock worth $107,000 after acquiring an additional 3,630 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Rezolute in the second quarter worth $25,000. Finally, Russell Investments Group Ltd. bought a new position in Rezolute in the third quarter valued at $61,000. 82.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Maxim Group upped their price target on Rezolute from $10.00 to $14.00 and gave the company a "buy" rating in a research report on Tuesday, June 2nd. HC Wainwright reissued a "buy" rating on shares of Rezolute in a report on Thursday, July 30th. Wedbush boosted their price objective on Rezolute from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Wednesday, June 3rd. Citizens Jmp upgraded Rezolute from a "market perform" rating to an "outperform" rating and set a $11.00 price objective on the stock in a research note on Wednesday, June 3rd. Finally, BTIG Research upped their price objective on shares of Rezolute from $5.00 to $6.00 and gave the company a "buy" rating in a report on Tuesday, June 2nd. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $9.38.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.